Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology

Standard of Care: Understanding Your Treatment Roadmap

At a Glance

The standard treatment for bone sarcoma involves a combination of chemotherapy and surgery to completely remove the tumor with negative margins. Protocols vary by subtype, such as MAP for osteosarcoma or surgery for chondrosarcoma. Discussing fertility preservation before starting chemo is critical.

The treatment of bone sarcoma is a marathon, not a sprint. It involves a coordinated “multimodal” approach where specialists in surgery, chemotherapy, and sometimes radiation work together to eliminate the cancer while preserving as much function as possible. Because these cancers are rare, the “standard of care” is based on decades of research showing which combinations of treatment work best for each subtype.

The Fertility Conversation You Must Have NOW

Because Osteosarcoma and Ewing Sarcoma frequently affect adolescents and young adults, it is critical to know that the intensive chemotherapy used to treat them carries a high risk of permanent infertility. Drugs like Cyclophosphamide and Ifosfamide can damage reproductive organs [1].

Before beginning any chemotherapy, you must talk to your care team about fertility preservation (such as sperm banking or egg/embryo freezing). This conversation needs to happen immediately, as the window of opportunity to act closes once treatment begins.

The Three Main Treatment Protocols

Your specific diagnosis determines the sequence and type of treatment you will receive. Often, treatment begins with neoadjuvant chemotherapy (treatment given before surgery to shrink the tumor), followed by surgery, and then adjuvant chemotherapy (treatment after surgery to finish the job).

1. Osteosarcoma: The “Chemo-Surgery-Chemo” Sandwich

  • The Regimen: The standard is the MAP regimen, which consists of three drugs: Methotrexate, Adriamycin (Doxorubicin), and Platin (Cisplatin) [2][3].
  • The Surgery: After several cycles of MAP, surgeons perform a wide resection to remove the tumor [4].
  • The Follow-up: After surgery, the adjuvant chemotherapy phase begins, continuing the MAP regimen [4].

2. Ewing Sarcoma: High Chemosensitivity

  • The Regimen: The standard protocol in North America is often VDC/IE, which alternates between two sets of drugs: Vincristine, Doxorubicin, and Cyclophosphamide (VDC) and Ifosfamide and Etoposide (IE) [5][6].
  • Local Control: Ewing cells are sensitive to radiation. Doctors may use radiation therapy alongside or instead of surgery. However, radiation carries a long-term risk of causing a secondary radiation-induced sarcoma later in life, so surgery is often preferred if negative margins can be achieved safely [7][8][9].

3. Chondrosarcoma: The Surgical Focus

Chondrosarcoma is generally chemoresistant, meaning traditional chemotherapy does not work well on it [10][7].

  • Main Treatment: Surgery is the primary and most effective treatment [7]. The goal is to remove the entire tumor with a wide margin of healthy tissue [11].
  • Targeted Therapies: For patients with advanced or metastatic chondrosarcoma, researchers are studying targeted therapies, such as IDH1 or IDH2 inhibitors, in clinical trials [12].

The Physical Reality of Treatment

Chemotherapy for bone sarcoma is intense. Patients typically require a central line or “chemo port” surgically placed in the chest to safely administer the drugs over many months. The acute side effects are rigorous: severe nausea, hair loss, fatigue, mouth sores (mucositis), and dangerously low white blood cell counts (neutropenia) that carry a high risk of infection. Your team will use supportive medicines, like anti-nausea drugs and white blood cell growth factors, to help you safely weather the storm.

During the surgical phase, you will face physical limitations. You may need to use crutches, a wheelchair, or a walker for an extended period to allow your bones to heal.

The Importance of Negative Margins (R0 Resection)

Regardless of the subtype, the surgical goal is always the same: negative margins, also known as an R0 resection [13][14].

  • What it means: When the pathologist looks at the edge of the removed tissue, they find a healthy “cuff” of normal cells with no cancer cells at the very edge [15].
  • Why it matters: If any cancer cells are left at the edge (positive margins), the risk of the cancer returning in that same spot (local recurrence) is significantly higher [13][15].

Choosing the Procedure: Limb-Salvage vs. Amputation

Today, limb-salvage surgery (removing the tumor and replacing the bone with a metal implant or donor bone) is possible for about 90% of patients [16][17].

  • Oncological Safety: As long as negative margins are achieved, there is no difference in survival rates between limb-salvage and amputation [18][19][20].

  • Rehabilitation: Limb-salvage often allows for a near-normal appearance, but it requires months of rigorous, intense physical therapy to regain strength and function. It may also come with permanent activity restrictions (like no high-impact running or jumping) [21][22].

  • When Amputation is Necessary: If the tumor has wrapped around major nerves or blood vessels, or if a negative margin cannot be achieved safely, an amputation is necessary to ensure the cancer is fully removed [23].

  • Next: Learn about Staging and Prognosis

Common questions in this guide

Why is fertility preservation important before starting bone sarcoma treatment?
Intensive chemotherapy drugs used for osteosarcoma and Ewing sarcoma carry a high risk of permanent infertility. It is critical to discuss options like sperm banking or egg freezing with a reproductive specialist before your treatment begins.
What is the standard chemotherapy regimen for osteosarcoma?
The standard treatment for osteosarcoma is the MAP regimen, which involves a combination of Methotrexate, Doxorubicin, and Cisplatin. This chemotherapy is usually given before surgery to shrink the tumor and continued after surgery.
What does a negative margin or R0 resection mean?
A negative margin, also known as an R0 resection, means the surgeon successfully removed the entire tumor with a border of healthy tissue around it. This is essential because leaving no cancer cells behind significantly lowers the risk of the cancer returning in that spot.
Is limb-salvage surgery as safe as amputation for bone sarcoma?
Yes, as long as the surgeon can safely achieve negative margins, there is no difference in survival rates between limb-salvage surgery and amputation. Limb-salvage is possible for the vast majority of patients today but requires rigorous physical therapy.
Does chemotherapy work for chondrosarcoma?
Traditional chemotherapy generally does not work well for chondrosarcoma. The primary and most effective treatment is surgery to completely remove the tumor with a wide margin of healthy tissue.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my options for fertility preservation, and can I see a reproductive specialist before we begin chemotherapy?
  2. 2.What is the exact chemotherapy regimen we are using, and what are its most common acute side effects?
  3. 3.How confident are you that we can achieve negative margins (R0 resection) with limb-salvage surgery?
  4. 4.(For Ewing Sarcoma) Will radiation be used as part of my local control, and what are the long-term risks to the bone and the risk of a secondary sarcoma?
  5. 5.What functional milestones should I expect to reach at 6 months and 1 year post-surgery during my physical therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

    Benjamin RS

    Advances in experimental medicine and biology 2020; (1257()):1-10 doi:10.1007/978-3-030-43032-0_1.

    PMID: 32483726
  2. 2

    A meta-analysis of the efficacy and safety of first-line chemotherapeutic agents for osteosarcoma.

    Li Z, Ma X, Wang Z, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2024; (33(5)):445-454 doi:10.17219/acem/170098.

    PMID: 37747442
  3. 3

    Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.

    Tsuda Y, Tsoi K, Parry MC, et al.

    The bone & joint journal 2020; (102-B(6)):795-803 doi:10.1302/0301-620X.102B6.BJJ-2019-1307.R1.

    PMID: 32475245
  4. 4

    Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

    Biermann JS, Hirbe A, Ahlawat S, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(4)).

    PMID: 40203873
  5. 5

    Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.

    Brennan B, Kirton L, Marec-Bérard P, et al.

    Lancet (London, England) 2022; (400(10362)):1513-1521 doi:10.1016/S0140-6736(22)01790-1.

    PMID: 36522207
  6. 6

    Local Lung Mass Masquerading a Very Aggressive Extraskeletal Ewing Sarcoma Presenting as Bilateral Paraparesis in a Young Adult.

    Pokal M, Sangani V, Balla M, et al.

    Journal of medical cases 2020; (11(12)):388-393 doi:10.14740/jmc3582.

    PMID: 34434351
  7. 7

    Systemic treatment for primary malignant sarcomas arising in craniofacial bones.

    Bielack SS

    Frontiers in oncology 2022; (12()):966073 doi:10.3389/fonc.2022.966073.

    PMID: 36158667
  8. 8

    Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

    Sand LG, Szuhai K, Hogendoorn PC

    International journal of molecular sciences 2015; (16(7)):16176-215 doi:10.3390/ijms160716176.

    PMID: 26193259
  9. 9

    Osteosarcoma and second malignant neoplasms: a case series.

    Geary RL, Corrigan LR, Carney DN, Higgins MJ

    Irish journal of medical science 2019; (188(4)):1163-1167 doi:10.1007/s11845-019-02027-2.

    PMID: 31054046
  10. 10

    Variations in contents of hyaluronan in the peritumoral micro-environment of human chondrosarcoma.

    Fede C, Stecco C, Angelini A, et al.

    Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2019; (37(2)):503-509 doi:10.1002/jor.24176.

    PMID: 30444002
  11. 11

    Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

    Song K, Shi X, Liang X, et al.

    International orthopaedics 2018; (42(12)):2941-2948 doi:10.1007/s00264-018-3942-7.

    PMID: 29681020
  12. 12

    Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets.

    Wagner MJ, Pimenta EM, Sweeney NW, et al.

    JCO precision oncology 2025; (9()):e2400592 doi:10.1200/PO-24-00592.

    PMID: 40117529
  13. 13

    Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.

    He F, Zhang W, Shen Y, et al.

    International journal of surgery (London, England) 2016; (36(Pt A)):283-292 doi:10.1016/j.ijsu.2016.11.016.

    PMID: 27840310
  14. 14

    Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?

    Bertrand TE, Cruz A, Binitie O, et al.

    Clinical orthopaedics and related research 2016; (474(3)):677-83 doi:10.1007/s11999-015-4359-x.

    PMID: 26013153
  15. 15

    The impact of surgical resection margins on outcomes for adults with head and neck osteosarcomas: A Canadian sarcoma research and Clinical Collaboration (CanSaRCC) study.

    Tzelnick S, Soroka HP, Tasnim N, et al.

    Oral oncology 2023; (145()):106495 doi:10.1016/j.oraloncology.2023.106495.

    PMID: 37478572
  16. 16

    Limb Salvage Surgery in Pediatric Patients with Osteosarcoma.

    Niculescu ȘA, Grecu AF, Gheonea C, Grecu DC

    Current health sciences journal 2024; (50(3)):360-367 doi:10.12865/CHSJ.50.03.03.

    PMID: 39574503
  17. 17

    Amputation Predisposes to Higher Cancer-Specific Mortality Than Limb Salvage Surgery in Pediatric Patients With Osteosarcoma of the Limbs: A Propensity Matching Analysis.

    Wang J, Tang J, Tan X, et al.

    Frontiers in surgery 2022; (9()):817051 doi:10.3389/fsurg.2022.817051.

    PMID: 35223978
  18. 18

    DISTAL (Distal tibia tumors treated with amputation versus limb Salvage): A systematic review and meta-analysis of oncologic, functional, and complication outcomes in malignant bone tumors.

    Garg N, Menon PH, Bajaj SK, et al.

    Journal of orthopaedics 2026; (73()):21-29 doi:10.1016/j.jor.2025.11.018.

    PMID: 41458943
  19. 19

    Bone Radiation-Induced Sarcomas: Outcomes Based on Histology and Surgical Treatment: A Systematic Review of the Literature.

    Inchaustegui ML, Larios F, Buteau JP, et al.

    JBJS reviews 2024; (12(8)) doi:10.2106/JBJS.RVW.24.00066.

    PMID: 39102470
  20. 20

    Prognostic analysis of telangiectatic osteosarcoma of the extremities.

    Zhong W, Luo W, Lin Z, et al.

    Frontiers in oncology 2022; (12()):1105054 doi:10.3389/fonc.2022.1105054.

    PMID: 36815074
  21. 21

    Amputation Versus Limb-Salvage Surgery as Treatments for Pediatric Bone Sarcoma: A Comparative Study of Survival, Function, and Quality of Life.

    Vale SS, Castro R, Andrade A, et al.

    Cureus 2025; (17(2)):e78543 doi:10.7759/cureus.78543.

    PMID: 40062064
  22. 22

    Efficacy of Neoadjuvant Chemotherapy plus Limb-Sparing Surgery for Osteosarcoma and Its Impact on Long-Term Quality of Life.

    Jing S, Ding F, Yuan Y, et al.

    Evidence-based complementary and alternative medicine : eCAM 2022; (2022()):1693824 doi:10.1155/2022/1693824.

    PMID: 35978993
  23. 23

    Clinical Statistical Analysis with Comparison between Pelvic and Non-pelvic Chondrosarcoma.

    Jami SA, Jiandang S, Roy BS, et al.

    Oman medical journal 2021; (36(3)):e271 doi:10.5001/omj.2021.65.

    PMID: 34239712

This page provides educational information on standard bone sarcoma treatments. Always consult your oncology and surgical team to determine the best treatment plan for your specific diagnosis.

Get notified when new evidence is published on Bone sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.